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ARTICLE OPEN
Impairment in delay discounting in schizophrenia and
schizoaffective disorder but not primary mood disorders
Hannah E. Brown1,2,3, Kamber L. Hart1,3, Leslie A. Snapper1,3, Joshua L. Roffman2,3 and Roy H. Perlis 1,3
A measure of planning and impulse control, the delay-discounting (DD) task estimates the extent to which an individual decreases
the perceived value of a reward as the reward is delayed. We examined cross-disorder performance between healthy controls (n=
88), individuals with bipolar disorder (n= 23), major depressive disorder (n= 43), and primary psychotic disorders (schizophrenia
and schizoaffective disorder; n= 51) on the DD task (using a $10 delayed larger reward), as well as the interaction of DD scores with
other symptom domains (cognition, psychosis, and affect). We found that individuals with schizophrenia and schizoaffective
disorder display signiﬁcantly greater rates of discounting compared to healthy controls, while individuals with a primary mood
disorder do not differ from healthy controls after adjustment for IQ. Further, impairment in working memory is associated with
higher discounting rates among individuals with schizophrenia and schizoaffective disorder, but cognitive dysfunction alone does
not account for the extent of impairment in DD. Taken together, these results suggest an impaired ability to plan for the future and
make adaptive decisions that are speciﬁc to individuals with psychotic disorders, and likely related to adverse functional outcomes.
More generally, this work demonstrates the presence of variation in impulsivity across major psychiatric illnesses, supporting the
use of a trans-diagnostic perspective.
npj Schizophrenia  (2018) 4:9 ; doi:10.1038/s41537-018-0050-z
INTRODUCTION
There is increased interest in understanding the aspects of
psychopathology that cross traditional psychiatric diagnostic
categories.1 One such trait that occurs trans-diagnostically is
impulsivity. Impulsive behavior can be characteristic of a
range of psychiatric diagnoses, including bipolar disorder
(BPAD), substance use disorders, attention-deﬁcit hyperactivity
disorder, and psychotic disorders. Impulsivity as a concept
spans multiple dimensions of behavior and cognition, including
motivation, information processing, and response output.2
One validated measure of impulsivity is an individual’s behavior
toward a certain reward, captured in the delay-discounting
(DD) task. “Discounting” refers to the extent to which the
perceived value of a reward is decreased when it is delayed.
Here, impulsivity is characterized by choosing a smaller,
immediate reward instead of a larger, delayed reward. The
steepness of the discounting rate determines the degree of
discounting (e.g., a lower rate indicates a greater willingness to
wait for a larger but delayed reward). The dimensional nature of
psychopathology can also be examined using the framework of
the National Institute of Mental Health Research Domain Criteria
(RDoC). Here, the DD task falls within both the positive valence
(reward/motivation) and cognitive (inhibition/suppression) RDoC
domains.1
Performance on the DD task may be informative about brain
reward circuitry, and may have direct clinical implications for
patients with primary psychotic disorders such as schizophrenia
and schizoaffective disorder (SCZ/SCAD), or primary mood
disorders such as BPAD or major depressive disorder (MDD), as
decreased preference for future rewards may directly impact their
ability to appreciate the necessity of long-term treatment or
planning for the future.2–5 In addition to planning behaviors, for a
subset of acutely suicidal depressed patients, DD task perfor-
mance may indicate increased risk for suicidal behavior.6
Previous work in single-disease cohorts has demonstrated an
elevated DD rate in individuals with SCZ/SCAD, BPAD, and MDD
when compared to healthy control individuals (HCs).7–9 While
healthy individuals with a less-steep rate of discounting have
better performance on working-memory tasks, less is known
about the effects of cognition on DD performance across
diagnostic groups.10 In the present study, we sought to under-
stand how impulsivity, as measured by the DD task, varies across
psychiatric disorders. We compared DD behaviors among
psychiatric diagnoses (SCZ/SCAD, BPAD, and MDD) and between
each individual psychiatric diagnosis and HCs. Then, in an effort to
understand how variation in impulsivity correlates with other
symptoms, we also characterized the interaction between
impulsivity and two other symptom domains, cognition and
depression. While the domains are intended to be orthogonal,
there are overlaps in brain systems underlying them, and further
examination of domain interactions is of clinical relevance.11
Based on previous work, we hypothesized that (1) individuals with
SCZ/SCAD, MDD, and BPAD would exhibit an elevated rate of DD
compared to HCs, and (2) measures of cognition, in particular
measures of executive function and strategy/planning behaviors,
would also correlate with the rate of DD.
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RESULTS
Demographic and clinical phenotypes
Demographic and clinical characteristics across diagnostic groups
are described in Table 1. The distribution of race and gender did
not differ signiﬁcantly across diagnostic groups; however, the HC
cohort was on average younger than those in the diagnostic
categories. Among the SCZ/SCAD population, the mean Positive
and Negative Syndrome Scale (PANSS) total score was 70.8 (SD=
14.7), indicating a moderate degree of severity of psychotic
symptoms. Both the BPAD and MDD groups (but not the HC or
SCZ groups) scored on average in the moderate depression range.
There was no difference in depression severity based on the
Inventory of Depressive Symptomatology—Self-Report (IDS-SR)
score between the BPAD and MDD group, and HCs had few or no
depressive symptoms. There was a signiﬁcant difference between
diagnostic groups by intelligence quotient (IQ); the SCZ/SCAD
group, and BPAD group had signiﬁcantly lower mean IQ
compared to HCs, and the SCZ/SCAD group had lower IQ scores
than individuals with MDD in Tukey post hoc comparisons.
On average, each participant completed 183.2 trials (SD= 43.2).
In repeated measures analysis of variance (ANOVA), there was no
effect of diagnosis on the number of trials administered, and there
was no interaction between trials per time point and diagnostic
category (Supplemental Fig. 1). There was a signiﬁcant effect of
time point on the number of trials administered. Participants
required fewer trials to reach an indifference point for the ﬁrst two
Table 1. Clinical characteristics and demographic information
SCZ/SCAD BPAD MDD HCs Test
statistic
p Post hoc comparisons
(n= 51) (n= 23) (n= 43) (n= 88)
Age (mean (SD)) 43.6 (12.7) 46.6 (12.4) 44.3 (13.6) 35.6 (10.4) p= 9.59 <0.001* HC < BP, SCZ/SCAD, and MDD
Sex (male) (%) 33 (64.7) 12 (52.2) 22 (51.2) 40 (45.5) χ2= 4.82 0.186
Race χ2= 7.95 0.9259
Caucasian (%) 37 (72.5) 18 (78.3) 35 (81.4) 63 (71.6)
African American (%) 6 (11.8) 4 (17.4) 4 (9.3) 10 (11.4)
Asian (%) 5 (9.8) 1 (4.3) 3 (7.0) 10 (11.4)
American Indian/Alaskan (%) 2 (3.9) 0 (0.0) 1 (2.3) 1 (1.1)
Other (%) 1 (2.0) 0 (0.0) 0 (0.0) 4 (4.5)
Current substance abuse— (%) 0 (0.0) 1 (4.3) 2 (4.7) 0 (0.0) χ2= 6.42 0.093
Current anxiety disorder (%) 12 (23.5) 14 (60.9) 22 (51.2) 0 (0.0) χ2= 63.36 <0.001* HC <MDD, BPAD, and SCZ/SCAD; SCZ/SCAD
< BPAD; and SCZ/SCAD <MDD
Current alcohol use disorder
(%)
1 (2.0) 0 (0.0) 4 (9.3) 0 (0.0) χ2= 11.34 0.01* HC <MDD
Current antipsychotic use (%) 45 (88.2) 15 (65.2) 9 (20.9) 0 (0.0) χ2= 126.06 <0.001* HC <MDD, BPAD, and SCZ/SCAD; MDD <
BPAD; MDD < SCZ/SCAD; and BPAD < SCZ/
SCAD
Current mood stabilizer use
(%)
13 (25.5) 9 (39.1) 6 (14.0) 0 (0.0) χ2= 32.63 <0.001* HC <MDD, BPAD, and SCZ/SCAD
Current antidepressant use (%) 22 (43.1) 15 (65.2) 17 (39.5) 0 (0.0) χ2= 73.44 <0.001* HC <MDD, BPAD, and SCZ/SCAD
Smoking status (%) 13 (25.5) 7 (30.4) 10 (23.3) 3 (3.4) χ2= 20.27 <0.001* HC <MDD, BPAD, and SCZ/SCAD
Clinical measures Mean (SD) Mean (SD) Mean (SD) Mean (SD)
PANSS positive 16.04 (6.2)
PANSS negative 22.8 (5.2)
PANSS general 31.9 (6.7)
PANSS total score 70.8 (14.7)
IDS-SR 16.5 (12.1) 30.2 (17.5) 26.9 (15.5) 4.0 (3.7) p= 58.78 <0.001* HC < BPAD, SCZ/SCAD, and MDD; SCZ/SCAD
< BPAD, MDD
Cognitive measures Mean (SD) Mean (SD) Mean (SD) Mean (SD)
IQ 92 (14.1) 96 (18.7) 105.8 (18) 107.7
(15.5)
p= 12.32 <0.001* HC > SCZ/SCAD, BPAD; SCZ/SCAD <MDD
AST 83.81
(13.90)
83.24
(18.76)
91.67
(8.00)
95.60
(4.63)
p= 17.82 <0.001* HC > BPAD, SCZ/SCAD; MDD > BP, SCZ/SCAD
SWM 39.19
(24.23)
40.05
(31.59)
33.76
(24.42)
16.19
(17.07)
p= 15.39 <0.001* HC < BPAD, MDD, and SCZ/SCAD
PAL 50.14
(51.59)
64.76
(80.19)
37.60
(50.15)
12.39
(27.69)
p= 11.38 <0.001* HC < BPAD, SCZ/SCAD
Ln(k) –3.65
(3.55)
–3.57
(2.77)
–4.94
(2.46)
–5.51
(2.12)
p= 6.76 <0.001* HC < BPAD, SCZ/SCAD
SCZ/SCAD schizophrenia/schizoaffective disorder, BPAD bipolar affective disorder, MDD major depressive disorder, HC healthy control, AST attention switching
task, SWM spatial working memory, PAL paired associates learning, IQ intelligence quotient, PANSS Positive and Negative Syndrome Scale, IDS-SR Inventory of
Depressive Symptomatology – Self-Report
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time points, as compared to all other time points. The average
number of trials by time point and by diagnostic group, as well as
the results of the repeated measures ANOVA and post hoc
comparisons, are shown in Supplemental Fig. 1. Sixty-ﬁve
participants (32%) with inconsistent discounting curves were
excluded from the primary analysis based on the criteria discussed
in the Data analysis section: 20 individuals with SCZ/SCAD, seven
individuals with BPAD, 11 individuals with MDD, and 27 HCs. In
general, excluded individuals were more likely to smoke and be
taking psychiatric medication, but otherwise did not differ
signiﬁcantly from included individuals in diagnosis or other
demographic features (Supplemental Table 1). Numerically,
excluded individuals also had lower IQ, although this difference
was not statistically signiﬁcant (Supplemental Table 1). A χ2 test of
homogeneity determined that diagnostic groups did not sig-
niﬁcantly differ in the proportion of inconsistent responders (χ2(2,
N= 205)= 0.73, p= 0.69).
After excluding individuals with inconsistent indifference points,
we analyzed the differences in rates of DD between diagnostic
categories using a one-way ANOVA and Tukey post hoc
comparisons. There was a signiﬁcant effect of diagnosis (F(3136)
= 4.897, p= 0.003), and in post hoc comparisons, individuals with
SCZ/SCAD had steeper discounting rates (lnk), as compared to HCs
and individuals with MDD (p= 0.004 and p= 0.043, respectively),
but there was no difference compared to individuals with BPAD
(Supplemental Table 2). Next, we examined the effects of
diagnosis on lnk in unadjusted models, as well as the unadjusted
effects of our covariates (age, gender, medication use (antide-
pressants, antipsychotics, and mood stabilizers), smoking, and IQ;
Table 2, left). In the unadjusted models, there was a signiﬁcant
effect of SCZ/SCAD diagnosis and BPAD diagnosis on the rate of
DD, compared to HCs, with both diagnostic groups having steeper
rates of discounting. There was no signiﬁcant difference in DD
rates between the MDD group and HCs. Univariate models also
identiﬁed signiﬁcantly steeper discounting rates due to age and
current antipsychotic use, and a signiﬁcantly less-steep discount-
ing rate due to IQ (Table 2, left). Subsequently, we created an
adjusted model to examine the adjusted effect of diagnosis on lnk
while controlling for the aforementioned covariates (Table 2,
right). In the adjusted model, IQ was a signiﬁcant predictor of the
rate of discounting: a one-point increase in IQ corresponded with
a 0.029 decrease in lnk (or, for every one standard-deviation
increase in IQ (15 points), lnk decreases by 0.44). Additionally in
the adjusted model (taking into account the effects of IQ), only a
diagnosis of SCZ/SCAD corresponded with a steeper rate of
discounting compared to HCs (Table 2, right; Fig. 1).
To better understand the impact of cognition on DD, and thus
the extent to which one measure of impulsivity is orthogonal with
cognition, we next examined the relationship between DD rate
and three neuropsychological tasks (spatial working memory
(SWM), paired associates learning (PAL), and attention-switching
task (AST)) by replacing IQ in our adjusted model with outcome
measures of these three tasks (Table 3). Within this model, there
was a steeper rate of DD for both SCZ/SCAD diagnosis and the
number of errors on the SWM task. Additionally, antipsychotic use
was associated with a less-steep rate of discounting. There was no
signiﬁcant effect of PAL or AST performance on the rate of DD in
any group. Thus, only a diagnosis of SCZ/SCAD remained a
signiﬁcant predictor of the steeper rate of DD after accounting for
the effects of SWM and antipsychotic use.
Next, we repeated our adjusted model (including the more
global measure of cognitive functioning, IQ), controlling for
comorbid psychiatric diagnoses, including anxiety disorders,
alcohol abuse/dependence, and substance abuse/dependence.
The results of this analysis are presented in Supplemental Table 3.
Again, individuals with SCZ/SCAD showed a steeper rate of
Table 2. Unadjusted and adjusted models of delay-discounting rate among consistent participants
Unadjusted models Adjusted model
β T-value p β T-value p
BPAD 1.088 2.122 0.036* 0.751 1.084 0.281
MDD 0.168 0.420 0.675 −0.044 −0.088 0.930
SCZ/SCAD 1.391 3.453 0.001* 1.437 2.090 0.039*
Age 0.033 2.610 0.010* 0.018 1.168 0.245
Sex 0.379 1.182 0.239 −0.018 −0.053 0.958
Antipsychotic Tx 1.004 2.941 0.004* −0.722 −1.207 0.230
Mood stabilizer Tx 0.795 1.850 0.066 0.304 0.628 0.531
Antidepressant Tx 0.569 1.701 0.091 0.221 0.511 0.610
Smoking status 0.501 0.990 0.324 −0.521 −0.964 0.337
IQ −0.038 −4.214 <0.001* −0.029 −2.636 0.009*
SCZ/SCAD schizophrenia/schizoaffective disorder, BPAD bipolar affective disorder, MDD major depressive disorder, HC healthy control, AST attention switching
task, SWM spatial working memory, IQ intelligence quotient, tx treatment
*p < 0.05
Fig. 1 Distribution of the rate of delay discounting across the
diagnostic category
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discounting, and an increase in IQ was associated with a
signiﬁcant decrease in the rate of discounting.
Finally, we sought to understand the relationship between
symptom severity and DD results, and performed separate
analyses within each diagnostic group incorporating diagnosis-
speciﬁc clinical measures (Table 4). Within the SCZ/SCAD model,
there was no effect of symptom severity on DD (as measured by
PANSS negative, positive, and general scores); however, an
increased score on the SWM task (increased number of errors
between each round) corresponded with a signiﬁcant increase in
the rate of DD within the SCZ/SCAD group after controlling for
clinical measures. Within the MDD group model, an increased
score on the IDS-SR (and thus greater depressive symptomatol-
ogy) corresponded to a less-steep rate of discounting. Within the
BPAD group model, depression severity did not have an effect on
the rate of discounting. Finally, among HCs, only an increase in the
SWM score signiﬁcantly corresponded to a steeper rate of DD.
DISCUSSION
In this study, we looked trans-diagnostically at one measure of
impulsivity and its interaction with other symptom domains.
Individuals with SCZ/SCAD demonstrated a greater rate of DD
compared to individuals with MDD and HCs—that is, those with
psychotic illness prefer smaller and sooner rewards compared to
larger and later rewards. Further, in adjusted models, we found
that performance on certain cognitive tasks also inﬂuenced DD;
individuals with more impairment on the SWM task demonstrate a
steeper rate of discounting, and individuals with a lower IQ
likewise have a steeper DD rate. Current treatment with
antipsychotic medication did not have a signiﬁcant effect on the
rate of DD in adjusted models. Among individuals with MDD, a
greater level of depressive symptomatology was predictive of a
less-steep rate of discounting (decreased lnk), but no such
relationship was observed among other mood disorders or HCs.
These ﬁndings underscore the important point that, despite
efforts to isolate individual areas of neuropsychological function
as orthogonal domains, there is correlation among cognitive
paradigms across psychiatric disorders.
Our ﬁnding that individuals with SCZ/SCAD exhibit greater rates
of DD compared to HCs extends previous reports.7,12–14 A steeper
rate of discounting among psychotic patients indicates an
impaired ability to plan for future consequences and make
adaptive decisions, which can have signiﬁcant functional con-
sequences in everyday life (e.g., saving money, planning meals,
and obtaining shelter). Within the SCZ/SCAD group as well as the
HC group, an increase in SWM errors correlates with a higher rate
of DD, ﬁndings that are, in general, in keeping with previous
literature examining working memory in relation to DD.7,10 SWM is
known to be impaired in individuals with SCZ, so it stands to
reason that impairment in SWM would covary with the rate of
discounting within the SCZ/SCAD cohort.15 SWM demands both
the ability to retain and manipulate visuospatial information, as
well as a degree of strategy and planning behaviors, which are
necessary components for optimal decision-making in the DD
task. Additionally, within this model, taking antipsychotic medica-
tion was associated with a less-steep rate of discounting. We
postulated that antipsychotic treatment could affect performance
on the DD task; antipsychotic medications modulate dopaminer-
gic brain circuits, and decreased dopamine receptor (including D2)
availability is associated with an increased rate of DD.16 However,
in this study, current treatment with antipsychotic medication
resulted in a less-steep rate of DD in adjusted models controlling
for cognitive domains. However, we did not examine speciﬁc
antipsychotic dosing, so we cannot exclude the possibility that
higher doses of antipsychotic medication with greater D2
Table 3. Adjusted model of delay-discounting rate including
cognitive measures
β T-value p
BPAD 0.956 1.315 0.191
MDD −0.192 −0.387 0.699
SCZ/SCAD 1.879 2.710 0.008*
Age 0.008 0.496 0.621
Sex 0.090 0.259 0.796
Antipsychotic Tx −1.263 −1.997 0.048*
Mood stabilizer Tx 0.346 0.695 0.488
Antidepressant Tx 0.170 0.393 0.695
Smoking status −0.728 −1.282 0.202
SWM 0.029 2.976 0.004*
AST −0.004 −0.221 0.826
PAL 0.001 0.166 0.869
SCZ/SCAD schizophrenia/schizoaffective disorder, BPAD bipolar affective
disorder, MDD major depressive disorder, HC healthy control, AST attention
switching task, SWM spatial working memory, PAL paired associates
learning, tx treatment
*p < 0.05
Table 4. Delay-discounting rate and symptom severity within diagnostic groups
SCZ/SCAD BPAD MDD HC
β T-value p β T-value p β T-value p β T-value p
Smoking status −0.284 −0.197 0.846 −0.971 −0.633 0.542 0.040 0.061 0.952 −1.466 −0.803 0.425
Age −0.038 −0.779 0.444 0.063 1.222 0.253 0.029 1.195 0.243 0.002 0.077 0.939
Sex −0.115 −0.101 0.920 0.830 0.673 0.518 0.148 0.289 0.775 0.531 1.188 0.240
IDS-SR score — — — 0.060 1.633 0.137 −0.042 −2.895 0.008* −0.063 −1.093 0.279
SWM 0.065 2.324 0.030* 0.003 0.148 0.885 0.003 0.210 0.835 0.033 2.507 0.015*
PANSS (negative) 0.141 1.269 0.218 — — — — — — — — —
PANSS (positive) 0.018 0.115 0.909 — — — — — — — — —
PANSS (general) −0.138 −1.088 0.289 — — — — — — — — —
SCZ/SCAD schizophrenia/schizoaffective disorder, BPAD bipolar affective disorder, MDD major depressive disorder, HC healthy control, PANSS Positive and
Negative Syndrome Scale, IDS-SR Inventory of Depressive Symptomatology – Self-Report
*p < 0.05
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blockade would impact DD rate differently (i.e., cause a steeper
rate of DD).
Looking trans-diagnostically, two other cognitive measures
(PAL, a measure of visual memory and learning, and AST, a
measure of executive functioning) do not affect performance on
the DD task. We postulated that performance on AST would affect
performance on the DD task, given that the DD task requires
planning behaviors. However, as discussed, the DD task is not
purely an executive-functioning measure, and thus is not
signiﬁcantly affected by AST performance. The DD task does not
allow for error processing or learning, since the participant is
instructed to respond instinctively; thus, the task measures one
component of impulsivity.17,18 For this reason, we did not expect
PAL to inﬂuence DD performance, since learning should not play a
role in task performance. Therefore, within working memory,
impairments in SWM speciﬁcally relate to increased rates of DD, as
compared to measures of executive functioning or learning.
Within the SCZ/SCAD group, we did not detect any association
between the severity of clinical symptoms (as measured by the
PANSS) and the rate of discounting, which is consistent with some
previous ﬁndings.7 Interestingly, studies in ﬁrst-degree family
members of individuals with SCZ/SCAD (depressed type) have not
identiﬁed abnormalities in DD, which might suggest that this is a
state rather than a trait-dependent phenomenon.14 While we did
examine the overall PANSS negative scores, one component of
motivational negative symptoms not directly addressed in this
study is effort-based decision-making, i.e., the effort an individual
expends for a particular reward. Thus, as the reward increases, so
should the effort expended to obtain the reward.19 Individuals
with SCZ/SCAD may be less motivated to pursue a reward or
cannot comprehend the structure of the reward itself, which may
directly affect their performance on the DD task.
In contrast to the SCZ/SCAD cohort, we did not ﬁnd a signiﬁcant
difference in the rate of DD between either MDD or BPAD
individuals and HCs. This lack of difference may be indicative of
the state of the participant at the time of testing. While manic
patients may have a greater rate of DD, our cohort of BPAD was
predominantly depressed, likely explaining the lack of difference
in the discounting rate between both MDD and BPAD and HCs.7
However, within just the MDD group, more severe depressive
symptoms were associated with a less-steep rate of DD. The
presence of moderate depression may prevent individuals from
appreciating the beneﬁt of any immediate gratiﬁcation, causing
them to put off future rewards. However, it is possible that with a
larger future reward (e.g., >$10), depressed individuals with MDD
will discount at higher rates, as noted in Pulcu et al.8 Additionally,
MDD symptoms are heterogeneous, and it is possible that
different symptoms affect DD performance to varying extents.
For example, those individuals who display more anhedonia may
have a less-steep rate of discounting compared to those who are
less anhedonic.20 Within the BPAD cohort, depressive symptoma-
tology did not correlate with the rate of DD; this may simply
reﬂect the modest size of the BPAD cohort yielding consistent
performance (n= 16).
One potential limitation to our study is the reward size offered
in the DD task. Participants chose between the sooner smaller
reward (SSR) and the larger later reward (LLR), which was ﬁxed at
$10. For some participants, this monetary amount may not be
signiﬁcantly large enough to delay, and thus they may choose the
SSR, regardless of amount. To this point, Wing et al.21 found that
reward size inﬂuenced the rate of discount (i.e., a smaller reward
resulted in a higher delay-discounting rate). Another limitation is
that there was no assessment of manic symptoms using a speciﬁc
clinical scale (e.g., Young Mania Rating Scale); rather, we relied
solely on the Structured Clinical Interview for DSM-IV (SCID)
assessment of manic symptoms. It is possible that if we used such
a specialized scale, more manic symptoms would be apparent,
and perhaps, a difference could be seen between a subgroup of
BPAD patients and HCs.
A third potential limitation is the exclusion of individuals who
are deemed inconsistent, based on the relationship between the
indifference points and the LLR. For example, a consistent choice
of the SSR is labeled inconsistent because the last indifference
point is not less than the ﬁrst indifference point by at least 10% of
the LLR, and thus does not ﬁt the hyperbolic model. However, this
pattern of choice may in fact be indicative of the underlying
psychopathology and disease state; for this reason, in contrast to
many prior studies, we examine and detect associations with
exclusion, and suggest that future studies should do the same.
Furthermore, as noted in previous studies, the monetary reward in
the DD task is hypothetical and thus potentially less impactful
than real payment; however, even hypothetical tasks have been
shown to produce similar discounting rates when compared to
tasks using real money.22
Finally, even though prior literature indicates an effect of
substance use on DD (and in particular cigarette smoking), low
rates of current substance use in our population preclude direct
examination of effects other than nicotine use.23 Recent work
demonstrates that elevated DD rate among SCZ/SCAD persists,
regardless of smoking behaviors, which is consistent with our
results.14
Taken as a whole, the present study illustrates signiﬁcant
variation in a speciﬁc measure of impulsivity across major
psychiatric disorders, supporting the use of such measurement
even in disorders where reward processing per se is not
understood to be the primary area of dysfunction. This work also
underscores the challenges in multidimensional assessment of
psychopathology: despite ongoing efforts to isolate individual
symptom measurements, many paradigms require intactness of
multiple symptom domains. Here, cognition (measured grossly by
IQ, and more speciﬁcally by SWM) associates with performance on
the DD task. Understanding the relationship between symptom
domains may allow for further clinical characterization using
dimensional measures, and may provide the opportunity for more
targeted therapeutic strategies. Considering the impact of
impulsive behavior on contributors to adverse psychiatric out-
comes, including substance abuse, treatment nonadherence,
impaired decision-making, and self-injury, further investigation
of this behavior—and the ways in which it interacts with diagnosis
and other symptoms—is warranted.
METHODS
Participants
Participants were recruited from the outpatient clinical setting, as part of a
systematic clinical assessment for a cellular biobanking study.24 The
Partners Institutional Review Board approved the study protocol and
informed consent procedure, and all studies were performed in
accordance with relevant guidelines and regulations. All participants
provided written informed consent. Participants ranged in ages from 20 to
65 years and represented four diagnostic categories: (1) 43 participants
with MDD, (2) 51 participants with primary psychotic disorder (SCZ (n= 33)
or SCAD (n= 18)), (3) 23 participants with BPAD, as well as (4) 88 HCs. An
expert clinician conﬁrmed the diagnosis for participants with psychiatric
illness and the lack of diagnosis for HCs using the Structured Clinical
Interview for DSM-IV (SCID)25 and the Mini International Neuropsychiatric
Interview Version 5.0.0 (MINI).26 For those individuals with a primary
psychotic disorder, psychotic symptoms were evaluated by a trained
physician rater using the PANSS.27 There was no active symptom
requirement for participation in the study. Smoking status was obtained
by a self-report: participants reported their smoking status over the past
2 weeks, and “smokers” were classiﬁed as those who reported smoking
between several days to nearly every day. Current alcohol use and other
substance use disorders were obtained using the MINI. Current medication
use was assessed with a questionnaire administered by the study clinician,
conﬁrming medication name, dose, and duration of the current treatment
episode. Medications were conﬁrmed by a query of electronic health
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records wherever available. The IDS-SR, a 30-item assessment of
depression severity, was administered to all participants.28 As part of the
cognitive battery described below, participants completed the Wechsler
Abbreviated Scale of Intelligence second edition (WASI-II) to determine the
full-scale IQ, using the vocabulary and matrix-reasoning subsections.29 HCs
were deﬁned as individuals having no Axis I psychiatric diagnosis by SCID
and MINI, and no intellectual disability (deﬁned by IQ <70). Participants
were excluded if they had intellectual disability, or a comorbid neurologic
illness, including Parkinson’s disease, multiple sclerosis, or Alzheimer’s
disease based upon clinical interview and review of electronic health
records.
Neuropsychiatric battery
In addition to the WASI-II, all participants completed a computerized
neuropsychiatric cognitive battery, the Cambridge Neuropsychological
Test Automated Battery (CANTAB), which includes testing of speciﬁc
cognitive domains.30 The present analyses focused on standard CANTAB
measures, including SWM, PAL, and AST. For SWM, we analyzed the
number of errors made between attempts, for PAL total errors, and for AST
percent correct trials. These tasks were selected based on validity and
ability to assess the relevant domains of cognition.
Delay-discounting tasks
Each participant was administered a DD task.17,31 In this DD task,
participants were given the choice between a SSR, and a set LLR of $10.
Reward levels for the sooner smaller reward varied between 50 cents and
$10. An example question is as follows: “would you rather have 3 dollars
now or 10 dollars in 365 days?” The time points for the LLR ranged from
immediately to 1 year (0, 2, 30, 180, and 365 days). Participants were
instructed to respond instinctively, as is standard administration practice.
As the participants answered questions, the program adjusted the amount
of the SSR based on their previous responses, and the participant
continued to answer until a point of indifference was reached for each
time point. The indifference point is the value at which the participant is
indifferent between the two choices.17
Data analysis
All analyses were done using R software, version 3.2.1.32 Since there was a
variable number of trials completed by a participant at each indifference
point, we conducted repeated measures ANOVA to determine the effect of
diagnostic category and time point on the number of trials administered.
Subsequently, we performed post hoc pairwise comparisons between time
points using paired two-sided t tests with Bonferroni corrections.
Then, in accordance with previously described methods, the indifference
points for each of the ﬁve time points were calculated for each participant.
As is standard in the literature, the ﬁve indifference points were used to
determine a best-ﬁt hyperbolic curve.33
Vp ¼ A
1þ k ´Dð Þ :
In this equation, Vp is the discounted value of the reward, A is the value
of the later larger reward ($10 in this study), k is the discounting rate for
the hyperbolic curve, and D is the amount of time between the choice and
the reward (delay).34 If the software could not validate an indifference
point, then that point was not used to ﬁt the curve, consistent with prior
studies.33 The hyperbolic discounting rate for time, k, was determined
using a nonlinear least-squares approach to ﬁt the model. A larger k
indicates a steeper rate of discounting (i.e., prefers smaller sooner rewards),
and thus greater impulsivity. A smaller k indicates a less-steep rate of
discounting (i.e., prefers larger later rewards). As in prior literature, we used
the natural log (ln) of k to normalize the distribution of k for all subsequent
analyses, since k has a strong positive skew.7,17
Individuals with inconsistent discounting curves—i.e., participants
whose indifference points could not be ﬁt using a hyperbolic curve—
were identiﬁed according to the model proposed by Johnson and Bickel.34
Speciﬁcally, participants were designated as having inconsistent discount-
ing curves if they (1) had an indifference point that increased by >20% of
the LLR ($2 in this paradigm) or (2) if the last indifference point was not
less than the ﬁrst indifference point by at least 10% of the LLR ($1 in this
paradigm).
Participants with inconsistent discounting curves were excluded from
the main analyses because their data are nonsystematic and cannot be
interpreted using a hyperbolic model.34 However, inconsistent
performance could be the result of disease-associated cognitive dysfunc-
tion. Therefore, rather than simply omitting these individuals, we began by
comparing excluded individuals to the remainder of the cohort. Multi-
variable logistic regression was used to compare individuals with
inconsistent and consistent indifference points, both across and within
diagnoses, examining the speciﬁc metrics relevant to each diagnostic
category (PANSS for SCZ/SCAD; IDS-SR for BPAD and MDD). Additionally, a
χ2 test of homogeneity was performed to determine if diagnostic groups
were comparable in the rate of inconsistency. Assuming 20 subjects per
group, with α= 0.05, power exceeds 80% to detect a minimum effect size
of 0.38.
Subsequent analyses focused on the consistent (remaining) cohort. First,
we performed a one-way ANOVA to compare the differences in DD rates
between all diagnostic groups and performed pairwise post hoc
comparisons of the discounting rate between diagnostic groups. Next,
we assessed the effects of diagnosis on DD in unadjusted linear-regression
models, as well as in an adjusted model incorporating age, sex, smoking
status, current use of a psychiatric medication, cognitive measures (IQ and
SWM, PAL, and AST), and depressive measures (IDS-SR score). We included
the relevant psychiatric medications (antipsychotics, antidepressants, and
non-antipsychotic mood stabilizers) in our adjusted models since use of all
three medications was present in each of the diagnostic groups.
Information about all classes of medication was obtained via a
questionnaire administered by a study clinician. Additionally, we repeated
the adjusted model, controlling for psychiatric comorbidities, including
anxiety disorders, alcohol abuse/dependence, and substance abuse/
dependence. We also compared DD performance within each individual
diagnostic category (SCZ/SCAD, BPAD, and MDD) to DD performance in
the HC group. In addition, to explore the impact of symptom severity on
DD, we created linear models speciﬁc to each diagnostic category. These
models included clinical assessments speciﬁc to the diagnostic category
(PANSS scores for patients with SCZ/SCAD, and IDS-SR scores for patients
with MDD and BPAD) and controlled for age, sex, smoking status, and SWM
shown to have a signiﬁcant effect in the previous model.
Data availability
De-identiﬁed data will be available from the authors upon request.
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